Leveraging the power of RNA & AI for diagnostics
ALCEDIAG Leveraging the power of RNA and AI for diagnostics

EDIT-B®

Blood test to differentiate unipolar depression from bipolar disorder

EDITOX®

Cell-based solutions to mimic drug impact on RNA editing

EDITECH®

Integrated platform from RNA / DNA sequencing to machine learning and AI

Meet us

European College of Neuropsychopharmacology (ECNP) Conference

From 11th to 14th October 2025 in Amsterdam

Join us on October 14th for the presentation of our latest research during Poster Session 4, at 12:35 pm CET. Our work titled “RNA editing signatures powered by artificial intelligence: a new frontier in differentiating schizophrenia, bipolar and schizoaffective disorders” (poster PS04-3308) will be presented by our CSO, Dr. Dinah Weissmann. Joining her will be our Deputy Scientific Director Dr. Francisco Santos Schneider.

Looking forward to discussing the latest advancements in Precision medicine, Artificial Intelligence and computational models, and Biomarkers!

Innovative Diagnostic Company

​ALCEDIAG is an innovative diagnostic company specializing in the development and commercialization of blood tests, monitoring solutions, and companion diagnostics, primarily for mental health. These offerings are based upon the company’s distinctive expertise in epigenetics, RNA, and Artificial Intelligence, complemented by neurosciences and psychiatry.

ALCEDIAG’s unique approach is protected by seven patent families and supported by a global network of Key Opinion Leaders, who serve both as advocate for and early adopt of ALCEDIAG’s solutions.